Axitinib Therapy Management Study

Pfizer

Status: Withdrawn

Conditions: Renal Cell Carcinoma

Treatments: Drug: Bavencio; Drug: Keytruda; Drug: Inlyta

Study type: Observational

Funder types: Industry

Identifiers

NCT04555603

A4061096

Details and patient eligibility

About

The objectives of the study is to describe axitinib therapy management through use of the data to be generated by ConcertAI

Full description

not mandatory

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Confirmed diagnosis of aRCC (Stage III, Stage IV (M0) or Stage IV (M1)) at any point
• Age 18 years or older at the time of aRCC diagnosis
• Received a qualifying IO-containing combination (nivolumab and ipilimumab, axitinib and pembrolizumab, or axitinib and avelumab) in the first regimen after aRCC diagnosis or axitinib monotherapy in any line

Exclusion criteria

• none